• Explore /
  • Poster
  • / First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.

First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.

Abstract Poster

Authors

null

Sandra P. D'Angelo

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Jeffrey Russell , Jessica Cecile Hassel , Celeste Lebbe , Bartosz Chmielowski , Guilherme Rabinowits , Patrick Terheyden , Isaac Brownell , Isabella Zwiener , Marcis Bajars , Meliessa Hennessy , Howard Kaufman , Sandra P. D'Angelo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02155647

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9530)

DOI

10.1200/JCO.2017.35.15_suppl.9530

Abstract #

9530

Poster Bd #

138

Abstract Disclosures

Similar Posters

First Author: Sandra P. D'Angelo

First Author: Astrid Blom Fily

First Author: Sandra P. D'Angelo

First Author: Irina Shapiro